Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04925284
Title	Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Recruitment	Active, not recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Exelixis
Indications	transitional cell carcinoma head and neck squamous cell carcinoma triple-receptor negative breast cancer Her2-receptor negative breast cancer hypopharynx cancer renal pelvis transitional cell carcinoma glottis squamous cell carcinoma ovarian cancer Advanced Solid Tumor laryngeal squamous cell carcinoma peritoneum cancer prostate adenocarcinoma esophagus squamous cell carcinoma lung non-small cell carcinoma bladder urothelial carcinoma ureter transitional cell carcinoma pancreatic adenocarcinoma cervical cancer oral cavity cancer fallopian tube cancer cervix carcinoma urethra transitional cell carcinoma oropharynx cancer
Therapies	XB002 Nivolumab + XB002
Age Groups:	senior \| adult
Covered Countries	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| BEL \| AUS